DUBLIN–(BUSINESS WIRE)–The “Painful Diabetic Neuropathy Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029” report has been added to ResearchAndMarkets.com’s offering.
The Painful Diabetic Neuropathy Drugs Market is forecasted to grow at a CAGR of 7% during the forecast period of 2019 to 2029.
The treatment includes several medications such as, Anticonvulsants, Tricyclic antidepressants, Serotonin-norepinephrine reuptake inhibitors, Opioid-like medications, Topical medications, Selective serotonin reuptake inhibitors & Opioids. The medicines inhaled in this treatment costs about a range of 8$ – 560$. They also have adverse effect as, nausea, headache, dizziness, peripheral edema, weight gain, constipation, diarrhea, anxiety, vomiting, Somnolence, insomnia & so on. The range of patients causing adverse effect may vary from 5 % to 60 %.
Diabetes has become one of the largest global health care diseases of the 21st century. According to the Centers for Disease Control and Prevention CDCP, the population prevalence of diabetes in North America is approaching 10% and is increasing by 5% each year. The number of people with diabetes rose from 108 million in 1980 to 422 million in 2014. The spread of diabetes has been emerging more rapidly in low & middle income countries than in high income countries. Approximately, 60 million people in the European Region are living with this disease, straining the region’s economies and health systems.
Some of the key players include Daiichi Sankyo Company, Eli Lilly and Company, Johnson & Johnson Services, Novartis AG, Pfizer Inc, Grunenthal GmbH, ViroMed Co, Collegium Pharmaceutical, Acorda Therapeutics, Zydus Pharmaceuticals, Mallinckrodt, Macleods Pharmaceuticals Ltd, Lupin Pharmaceuticals.
This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment are calculated for the forecast period from 2021 to 2029.
Key questions answered in this report
- What are the key market segments in current scenario and in the future by product categories?
- What are the key market segments in current scenario and in the future by regions?
- What is the key impact of Covid-19 over market revenues and market determinants in the Painful Diabetic Neuropathy Drugs market?
- What are the primary and secondary macro and micro factors influencing the market growth currently and during the forecast period?
- What are the primary and secondary macro and micro factors deterring the market growth currently and during the forecast period?
- How to overcome the current market challenges and leverage the opportunities in each of the market segment?
- Who are the key players in the Painful Diabetic Neuropathy Drugs market and what are their key product categories and strategies?
-
What are the key strategies – mergers/acquisitions/R&D/strategic partnerships etc that companies are deploying to enhance market revenues and growth?
Key Topics Covered:
Chapter 1. Preface
Chapter 2. Executive Summary
Chapter 3. Painful Diabetic Neuropathy Drugs Market: Market Dynamics and Future Outlook
Chapter 4. Painful Diabetic Neuropathy Market, by Drug Type, 2019 – 2029 (US$ Mn)
Chapter 5. Painful Diabetic Neuropathy Drugs Market, by Disease Type, 2019 – 2029 (US$ Mn)
Chapter 6. Painful Diabetic Neuropathy Drugs Market, by Application area, 2019 – 2029 (US$ Mn)
Chapter 7. Painful Diabetic Neuropathy Drugs Market, by Region, 2019 – 2029 (US$ Mn)
Chapter 8. Europe PDND Market Analysis, 2019 – 2029
Chapter 9. Asia Pacific PDND Market Analysis, 2019 – 2029
Chapter 10. Latin America PDND Market Analysis, 2019 – 2029
Chapter 11. Middle East & Africa (MEA) PDND Market Analysis, 2019 – 2029
Chapter 12. Company Profiles
- Daiichi Sankyo Company
- Eli Lilly and Company
- Johnson & Johnson Services
- Novartis AG
- Pfizer Inc
- Grunenthal GmbH
- ViroMed Co
- Collegium Pharmaceutical
- Acorda Therapeutics
- Zydus Pharmaceuticals
- Mallinckrodt
- Macleods Pharmaceuticals Ltd
- Lupin Pharmaceuticals.
For more information about this report visit https://www.researchandmarkets.com/r/wveo41
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900